Survivin, a target to modulate the radiosensitivity of Ewing's sarcoma

Strahlentherapie und Onkologie

Volumn 188, Issue 11, 2012, Pages 1038-1047

  Greve, B ^a   Sheikh Mounessi, F ^a   Kemper, B ^a   Ernst, I ^a   Gotte M ^a   Eich, H T ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Birc5; Ewing's sarcoma; Radiosensitivity; Survivin; YM155

Indexed keywords

HISTONE H2AX; MESSENGER RNA; SEPANTRONIUM BROMIDE; SMALL INTERFERING RNA; SURVIVIN;

APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CELL CYCLE PHASE; CELL DIVISION; CELL PROLIFERATION; COLONY FORMATION; DNA REPAIR; DOUBLE STRANDED DNA BREAK; EWING SARCOMA; GENE SILENCING; IN VITRO STUDY; PROTEIN EXPRESSION; RADIATION DOSE; RADIOSENSITIVITY; RNA EXTRACTION; SARCOMA CELL;

APOPTOSIS; BLOTTING, WESTERN; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASTIC STEM CELLS; RADIATION TOLERANCE; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SARCOMA, EWING;

EID: 84867946834     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-012-0223-z     Document Type: Article

References (44)

1. Kushner BH, Meyers PA (2001) How effective is dose-intensive/ myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. J Clin Oncol 19:870-880
2. Khoury JD (2005) Ewing sarcoma family of tumors. Adv Anat Pathol 12:212-220
3. Braun Y (2005) Characterization of telomerase as therapeutic targt for the treatment of small round blue cell tumors. Dissertation
4. Sheplan LJ, Juliano JJ (2010) Use of radiation therapy for patients with soft-tissue and bone sarcomas. Cleve Clin J Med 77(Suppl 1):27-29
5. Mita AC, Mita MM, Nawrocki ST, Giles FJ (2008) Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 14:5000-5005
6. Romagnoli M, Seveno C, Bataille R, Barille-Nion S (2008) Survivin in cancerology: molecular aspects and therapeutic applications. Med Sci (Paris) 24:821-827
7. Pennati M, Folini M, Zaffaroni N (2008) Targeting survivin in cancer therapy. Expert Opin Ther Targets 12:463-476
8. Altieri DC (2003) Survivin and apoptosis control. Adv Cancer Res 88:31-52
9. Capalbo G, Dittmann K, Weiss C et al (2010) Radiation-induced survivin nuclear accumulation is linked to DNA damage repair. Int J Radiat Oncol Biol Phys 77:226-234
10. Abdraboh ME, Gaur RL, Hollenbach AD et al (2011) Survivin is a novel target of CD44-promoted breast tumor invasion. Am J Pathol 179:555-563
11. Reichert S, Rodel C, Mirsch J et al (2011) Survivin inhibition and DNA double-strand break repair: a molecular mechanism to overcome radioresistance in glioblastoma. Radiother Oncol 101(1):51-58
12. Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917-921
13. Capalbo G, Rodel C, Stauber RH et al (2007) The role of survivin for radiation therapy. Prognostic and predictive factor and therapeutic target. Strahlenther Onkol 183:593-599
14. Yamamoto H, Ngan CY, Monden M (2008) Cancer cells survive with survivin. Cancer Sci 99:1709-1714
15. Erpolat OP, Gocun PU, Akmansu M et al (2012) High expression of nuclear survivin and Aurora B predicts poor overall survival in patients with head and neck squamous cell cancer. Strahlenther Onkol 188(3)248-254
16. Weiss C, Romer F von, Capalbo G et al (2009) Survivin expression as a predictive marker for local control in patients with high-risk T1 bladder cancer treated with transurethral resection and radiochemotherapy. Int J Radiat Oncol Biol Phys 47(5):1455-1460
17. Rodel F, Frey B, Leitmann W et al (2008) Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models. Int J Radiat Oncol Biol Phys 71:247-255
18. Pfeifer D, Wallin A, Holmlund B, Sun XF (2009) Protein expression following gamma-irradiation relevant to growth arrest and apoptosis in colon cancer cells. J Cancer Res Clin Oncol 135(11):1583-1592
19. Andersen MH, Sorensen RB, Schrama D et al (2008) Cancer treatment: the combination of vaccination with other therapies. Cancer Immunol Immunother 57:1735-1743
20. Sprenger T, Rodel F, Beissbarth T et al (2011) Failure of downregulation of survivin following neoadjuvant radiochemotherapy in rectal cancer is associated with distant metastases and shortened survival. Clin Cancer Res 17:1623-1631
21. Liao CP, Adisetiyo H, Liang M, Roy-Burman P (2010) Cancer stem cells and microenvironment in prostate cancer progression. Horm Cancer 1:297-305
22. Greve B, Kelsch R, Spaniol K et al (2012) Flow cytometry in cancer stem cell analysis and separation. Cytometry A 81(4):248-293 (Epub ahead of print)
23. Greve B, Dreffke K, Rickinger A et al (2009) Multicentric investigation of ionising radiation-induced cell death as a predictive parameter of individual radiosensitivity. Apoptosis 14:226-235
24. Blattmann C, Oertel S, Thiemann M et al (2012) Suberoylanilide hydroxamic acid affects gammaH2AX expression in osteosarcoma, atypical teratoid rhabdoid tumor and normal tissue cell lines after irradiation. Strahlenther Onkol 188:168-176
25. Erp PE van, Brons PP, Boezeman JB et al (1988) A rapid flow cytometric method for bivariate bromodeoxyuridine/DNA analysis using simultaneous proteolytic enzyme digestion and acid denaturation. Cytometry 9:627-630
26. Kemper B, Carl D, Höink A et al (2006) Modular digital holographic microscopy system for marker free quantitative phase contrast imaging of living cells. Proceedings of SPIE 6191:T-1-T-8
27. Carl D, Kemper B, Wernicke G, Bally G von (2004) Parameter-optimized digital holographic microscope for high-resolution living-cell analysis. Appl Opt 43:6536-6544
28. Kemper B, Carl D, Schnekenburger J et al (2006) Investigation of living pancreas tumor cells by digital holographic microscopy. J Biomed Opt 11:34005
29. Kemper B, Bauwens A, Vollmer A et al (2010) Label-free quantitative cell division monitoring of endothelial cells by digital holographic microscopy. J Biomed Opt 15:036009
30. Carpenter AE, Jones TR, Lamprecht MR et al (2006) CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol 7:R100
31. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408
32. Marusawa H, Matsuzawa S, Welsh K et al (2003) HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J 22:2729-2740
33. Dohi T, Xia F, Altieri DC (2007) Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. Mol Cell 27:17-28
34. Jacob NK, Cooley JV, Shirai K, Chakravarti A (2012) Survivin splice variants are not essential for mitotic progression or inhibition of apoptosis induced by doxorubicin and radiation. Onco Targets Ther 5:7-20
35. Lens SM, Vader G, Medema RH (2006) The case for Survivin as mitotic regulator. Curr Opin Cell Biol 18:616-622
36. Kappler M, Bache M, Bartel F et al (2004) Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53. Cancer Gene Ther 11:186-193
37. Wolanin K, Magalska A, Mosieniak G et al (2006) Curcumin affects components of the chromosomal passenger complex and induces mitotic catastrophe in apoptosis-resistant Bcr-Abl-expressing cells. Mol Cancer Res 4:457-469
38. Satoh T, Okamoto I, Miyazaki M et al (2009) Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res 15:3872-3880
39. Giaccone G, Zatloukal P, Roubec J et al (2009) Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol 27:4481-4486
40. Iwasa T, Okamoto I, Suzuki M et al (2008) Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res 14:6496-6504
41. Church DN, Talbot DC (2012) Survivin in solid tumors: rationale for development of inhibitors. Curr Oncol Rep 14:120-128
42. Weiss C, Romer F von, Capalbo G et al (2009) Survivin expression as a predictive marker for local control in patients with high-risk T1 bladder cancer treated with transurethral resection and radiochemotherapy. Int J Radiat Oncol Biol Phys 74:1455-1460
43. Shirai K, Suzuki Y, Oka K et al (2009) Nuclear survivin expression predicts poorer prognosis in glioblastoma. J Neurooncol 91:353-358
44. Maldegem AM van, Hogendoorn PC, Hassan AB (2012) The clinical use of biomarkers as prognostic factors in Ewing sarcoma. Clin Sarcoma Res 2(1):7